Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.

Ziyue ZhouChenglong FangLi WangJing LiYunjiao YangLi ZhangShangyi JinXiaofeng ZengXinping Tian

Published in: RMD open (2024)

Baricitinib 4 mg daily is effective for refractory TAK and is well tolerated.

Keyphrases